CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

CVRx, Inc.

CVRx provides a therapy option for heart failure through the Barostim device, which stimulates baroreceptors to regulate heart, kidney, and vascular function.

CVRx

CVRx | Barostim | 13,168 followers on LinkedIn. CVRx’s Barostim is a breakthrough technology that stimulates the body’s natural baroreflex to treat heart failure | CVRx is a commercial stage, public (NASDAQ: CVRX) medical devices company located in Minneapolis, Minnesota. The company has developed proprietary implantable technology for the treatment of high blood pressure and heart failure. Barostim™ triggers carotid baroreceptors - the body’s own natural blood flow regulation system - which signals the brain to regulate cardiovascular function.

Human Resources Executive

Tonya Austin

CVRx is partnering with medical professionals to use the power of the brain to help improve the lives of heart failure patients.

Parker Knight

Creative Director

Jonathan McLellan

Barostim | Outsmart the Heart

Josh Gonzalez, CCDS

CVRx | Barostim

Join our upcoming webinar with MedAxiom - An ACC Company to learn how #Barostim , a novel device therapy, targets neurohormonal pathways to improve #heartfailure symptoms. 📅 Date: Tuesday, Nov. 19, 1:00 PM EST 👨⚕️ Guest Faculty: Bonnie Handke, RN, MBA , Jim Kreiner, MHA , Patrick McCann , MD 🔗 Register Now: https://lnkd.in/gkTpsc2B

We are pleased to announce that the Centers for Medicare and Medicaid (CMS) assigned the Barostim implant procedure to New Technology Ambulatory Payment Classification (APC) 1580. “We applaud this action by CMS, which appropriately recognizes the resource requirements associated with the Barostim implant procedure in the outpatient setting. We appreciate the support from the CMS Hospital Outpatient Physician Advisory Panel, medical societies, and the hospital and physician community throughout the public comment period,” said Kevin Hykes , President and CEO of CVRx. Read the full press release: https://barost.im/3YRr8WO

We're at the SEAHEC Novant Regional Conference - stop by to learn how #Barostim targets the neurohormonal pathway to improve #heartfailure symptoms.

🎧 Tune in to the first episode of The Brain-Heart Continuum podcast with Philip Adamson, MD, MSc, FACC, FESC, FRCP (Ed) , Chief Medical Officer, CVRx. Dr. Adamson teams up with Dr. Samuel F. Sears to explore the significant impact #heartfailure has on patients' quality of life. Listen in to hear their insights! https://barost.im/4dJtdId

Today we announced our third quarter results and provided a business outlook for the rest of 2024. We are pleased to share these milestones: -Active US implanting centers increased 31% over prior year Q3 -US HF revenue increased 30% over prior year Q3 -Increased worldwide revenue 27% over prior year Q3 -CMS reassigned Barostim to a higher paying MS-DRG for inpatient procedures -AMA CPT® Editorial Panel accepted new CPT Category I codes for Barostim -New quality of life data was published in JACC: Heart Failure Learn more: https://barost.im/3AgAnGu

This past weekend, our team was happy to support the Kansas and Missouri ACC Scientific Session. Thanks to the attendees who stopped by to learn about #Barostim for the improvement of #heartfailure symptoms!

We're honored to support Drs. Eric Trestman and Harsh Patel and the team at Townsen Memorial Hospital on their first #Barostim implant. Their patients now have access to a novel device therapy for #heartfailure symptom improvement beyond GDMT alone.

JOIN US TODAY for a webinar where two leading heart failure specialists and an HF program leader will share their experience, perspective, and outcomes incorporating Barostim into their comprehensive advanced heart failure programs. Register now! https://ow.ly/mJyR50TSyqM

Cardiovascular Business

Tune in tomorrow at 2 pm ET to hear leading heart failure specialists ( Peter Eckman , MD and Pujan Patel , MD) and a HF program leader ( Gordon B. Wesley DBA, FACHE ) share their experience incorporating #Barostim into their comprehensive advanced HF programs. Bonnie Handke, RN, MBA will dig into the reimbursement and payment landscape that’s helping programs grow and thrive. Register here: https://lnkd.in/gD_fhn-d

We're proud to partner with Drs. Jeko Madjarov and John Rommel and the team at Novant Health New Hanover Regional Medical Center on their first #Barostim implant. Their patients now have access to a novel device therapy to improve #heartfailure symptoms.

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	6.26M -	6.05M 3.26%	13.04M 115.36%	22.47M 72.36%	39.30M 74.89%
cost of revenue	1.68M -	1.44M 14.44%	3.64M 152.78%	5.00M 37.34%	6.26M 25.15%
gross profit	4.57M -	4.61M 0.85%	9.40M 103.69%	17.47M 85.93%	33.04M 89.12%
selling and marketing expenses
general and administrative expenses
selling general and administrative expenses	6.11M -	9.72M 59.14%	27.86M 186.74%	50.05M 79.61%	64.51M 28.90%
research and development expenses	8.66M -	6.41M 26.00%	7.50M 17.02%	9.95M 32.68%	11.63M 16.89%
other expenses	-2.65M -	-40K 98.49%	-14.80M 36,900%	1.37M 109.28%
cost and expenses	16.45M -	17.57M 6.78%	39.00M 122.03%	65.00M 66.64%	82.40M 26.77%
operating expenses	14.77M -	16.13M 9.20%	35.36M 119.28%	60.00M 69.66%	76.14M 26.91%
interest expense	1.72M -	2.47M 43.60%	2.22M 10.16%	165K 92.56%	-1.80M 1,190.30%
ebitda	-12.78M -	-11.48M 10.21%	-40.77M 255.15%	-41.15M 0.95%	-43.10M 4.74%
operating income	-10.19M -	-11.51M 12.95%	-25.97M 125.53%	-42.53M 63.77%	-43.10M 1.35%
depreciation and amortization	-2.59M -	35K 101.35%	-14.80M 42,385.71%	1.37M 109.28%
total other income expenses net	-4.37M -	-2.51M 42.51%	-17.02M 578.05%	1.21M 107.10%	2.05M 69.78%
income before tax	-14.56M -	-14.02M 3.68%	-42.99M 206.52%	-41.32M 3.88%	-41.05M 0.65%
income tax expense	73K -	85K 16.44%	91K 7.06%	109K 19.78%	-147K 234.86%
net income	-14.63M -	-14.11M 3.58%	-43.08M 205.32%	-41.43M 3.83%	-41.20M 0.55%
weighted average shs out	10.35M -	363.40K 96.49%	10.36M 2,750.89%	20.53M 98.19%	20.75B 100,978.94%
weighted average shs out dil	10.35M -	363.40K 96.49%	10.36M 2,750.89%	20.53M 98.19%	20.75B 100,978.94%
eps	-1.41 -	-38.83 2,653.90%	-4.16 89.29%	-2.02 51.44%	-0.00 99.90%
epsdiluted	-1.41 -	-38.83 2,653.90%	-4.16 89.29%	-2.02 51.44%	-0.00 99.90%

COM:CVRX

CVRx

Last Close

14.49

14/02 21:00

Market Cap

154.41M

Beta: -

Volume Today

282.67K

Avg: -

Preview